Retapamulin is a topical antibiotic agent used for the treatment of impetigo caused by methicillin-susceptible Staphylococcus aureus or Streptococcus pyogenes. Retapamulin, marketed by GlaxoSmithKline as the ointment Altabax, is an antibiotic for skin infections like impetigo.
- Mechanism
- Curator reviewed
Retapamulin is a bacterial protein synthesis inhibitor belonging to a class of compounds called pleuromutilins. These compounds inhibit the initiation of protein synthesis by binding to a specific site on the 50S subunit of bacterial ribosome (domain V of 23S rRNA). This binding site involves ribosomal protein L3 and is in the region of the ribosomal P site and peptidyl transferase center. By virtue of binding to this site, pleuromutilins inhibit peptidyl transfer, block P-site interactions, and prevent the normal formation of active 50S ribosomal subunits.
- Primary indication
- For use in adults and pediatric patients aged 9 months and older for the topical treatment of impetigo (up to 100 cm2 in total area in adults or 2% total body surface area in pediatric...Curator reviewed · 2 structured indications
- Formula / weight
- C30H47NO4S · 517.763 g/mol (avg)
- First approval
- Canada, 2008 · United States, 2007
- Code names
- SB-275833
- Brand names
Resolves to
STZYTFJPGGDRJD-NHUWBDDWSA-NSMILES[H][C@@]12C(=O)CC[C@]11CC[C@@H](C)[C@@]2(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]1C)OC(=O)CS[C@H]1C[C@@H]2CC[C@H](C1)N2CWhat you can answer from here — as of September 14, 2026
Which drugs share a target with Retapamulin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account